Skip to main content

Tweets

NEJM Review Article on "Cryoglobulinemia — One Name for Two Diseases " (sign up for free read) https://t.co/RFLKBeze3a https://t.co/eA3SLmPMdj
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
EULAR has announced its new, open access journal - EULAR Rheumatology Open (ERO) https://t.co/PWPXZ4H2Ku https://t.co/7kHcUpLFXD
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
#SLE and biologics (approved & under study) - Full read review: Anifrolumab Belimumab Ocrelizumab Obinutuzumab Ofatumumab Veltuzumab Epratuzumab Tocilizumab Secukinumab Ustekinumab Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX. Join the Revolution in Rheumatology Education! https://t.co/ygjZRMVkOZ

Dr. John Cush @RheumNow ( View Tweet )

1 year 3 months ago
Men and Women Process Pain Differently Men and women experience pain relief differently; a new study may help explain why women have more chronic pain and are less responsive to opioid treatments. https://t.co/MYWAZnqGmA https://t.co/TxofSlsI4M
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Health Disparities in DMARD Use in RA A UK study shows biological and targeted synthetic DMARD (b/tsDMARDs) use in newly diagnosed rheumatoid arthritis (RA) varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply. https://t.co/t7O99FM7fQ https://t.co/CtvfblpPUo
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Cardiovascular health (CVH) is critical in arthritis care. NHANES study 5919 arthritis pts finds 10-point incr, in CVH score yielded significantly lower all-cause mortality risk (adj HR 0.72; 0.67–0.79); best results with OA/DJD, more than inflammatory arthritis.… https://t.co/etBbH7bH1D https://t.co/1is2VlT5sl
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
ACR and Congress Address “Damaging” Cuts to Medicare MD Payments The ACR commended the 233 bipartisan representatives who signed a letter urging House Speaker Mike Johnson (R-LA) and Minority Leader Hakeem Jeffries (D-NY) to support legislative action to address “damaging”… https://t.co/nVhRAeBf7y https://t.co/GwQTAi7GR1
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Eu Heart J - Cardiometabolic risk factors in RA Pregancy rose in last 15 yrs. RA-Preg at higher risk of preeclampsia, peripartum cardiomyopathy, arrhythmias, acute kidney injury, venous thromboembolism during hospitalizations. https://t.co/7SnjWFluCf https://t.co/H93ELPZWWz
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
GWAS study of 2.6 million people (120,295 w/ prevalent gout) detected 377 loci & 410 independent genes (149 prev unreported), includes genes of inflammation, epigenetic remodeling, cell osmolarity, NLRP3 activity, & clonal hematopoiesis (CHIP) https://t.co/GmXWtTlJkO https://t.co/xPK2Iy3NRj
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
×